Mitchell Kronenberg

Mitchell Kronenberg

Auto-generated profile, based on publicly available information

Mitchell Kronenberg

La Jolla Institute for Immunology, La Jolla, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2018 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
CCCatherine M. Crosby
Catherine M. Crosby
MKMitchell Kronenberg
Mitchell Kronenberg

18 April 2016 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
IEIsaac Engel
Isaac Engel
GSGregory Seumois
Gregory Seumois
LCLukas Chavez
Lukas Chavez
DSDaniela Samaniego-Castruita
Daniela Samaniego-Castruita
BWBrandie White
Brandie White
MKMitchell Kronenberg
Mitchell Kronenberg

15 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
DGDalia E. Gaddis
Dalia E. Gaddis
LPLindsey E. Padgett
Lindsey E. Padgett
RWRunpei Wu
Runpei Wu
CMChantel McSkimming
Chantel McSkimming
VRVeronica Romines
Veronica Romines
CHCatherine C. Hedrick
Catherine C. Hedrick
Regulatory T (Treg) cells contribute to the anti-inflammatory response during atherogenesis. Here we show that during atherogenesis Treg cells lose Foxp3 expression and their immunosuppressive function, leading to the conversion of a fraction of these cells into T follicular helper (Tfh) cells. We show that Tfh cells are pro-atherogenic and that their depletion reduces atherosclerosis. Mechanistically, the conversion of Treg cells to Tfh cells correlates with reduced expression of IL-2Rα and pSTAT5 levels and increased expression of IL-6Rα. In vitro, incubation of naive T cells with oxLDL prevents their differentiation into Treg cells. Furthermore, injection of lipid-free Apolipoprotein AI (ApoAI) into ApoE−/− mice reduces intracellular cholesterol levels in Treg cells and prevents their conversion into Tfh cells. Together our results suggest that ApoAI, the main protein in high-density lipoprotein particles, modulates the cellular fate of Treg cells and thus influences the immune response during atherosclerosis.

1 January 2015
Verified
Book Chapter
Closed access
SCShilpi Chandra
Shilpi Chandra
MKMitchell Kronenberg
Mitchell Kronenberg

21 December 2020 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
VCVivek Chandra
Vivek Chandra
SBSourya Bhattacharyya
Sourya Bhattacharyya
BSBenjamin J. Schmiedel
Benjamin J. Schmiedel
AMAriel Madrigal
Ariel Madrigal
CGCristian Gonzalez-Colin
Cristian Gonzalez-Colin
PVPandurangan Vijayanand
Pandurangan Vijayanand

4 May 2022 in Nature
Verified
Journal Article
Open access
PDF file
SESimon Eschweiler
Simon Eschweiler
CRCiro Ramírez-Suástegui
Ciro Ramírez-Suástegui
YLYingcong Li
Yingcong Li
EKEmma King
Emma King
LCLindsey Chudley
Lindsey Chudley
COChristian H. Ottensmeier
Christian H. Ottensmeier
Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies1–3. Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour immunity4,5, its effect on solid tumours in humans remains unclear. Here we assessed the effects of the PI3Kδi AMG319 in human patients with head and neck cancer in a neoadjuvant, double-blind, placebo-controlled randomized phase II trial (EudraCT no. 2014-004388-20). PI3Kδ inhibition decreased the number of tumour-infiltrating regulatory T (Treg) cells and enhanced the cytotoxic potential of tumour-infiltrating T cells. At the tested doses of AMG319, immune-related adverse events (irAEs) required treatment to be discontinued in 12 out of 21 of patients treated with AMG319, suggestive of systemic effects on Treg cells. Accordingly, in mouse models, PI3Kδi decreased the number of Treg cells systemically and caused colitis. Single-cell RNA-sequencing analysis revealed a PI3Kδi-driven loss of tissue-resident colonic ST2 Treg cells, accompanied by expansion of pathogenic T helper 17 (TH17) and type 17 CD8+ T (TC17) cells, which probably contributed to toxicity; this points towards a specific mode of action for the emergence of irAEs. A modified treatment regimen with intermittent dosing of PI3Kδi in mouse models led to a significant decrease in tumour growth without inducing pathogenic T cells in colonic tissue, indicating that alternative dosing regimens might limit toxicity.